NCT02332720View on ClinicalTrials.gov

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

PHASE2CompletedINTERVENTIONAL

Enrollment

413

Participants

Timeline

Start Date

January 28, 2015

Primary Completion Date

September 19, 2016

Study Completion Date

May 3, 2017

Conditions

Hepatitis C

Interventions

DRUG

Grazoprevir

Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.

DRUG

Uprifosbuvir

Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.

DRUG

Elbasvir

Part A: one elbasvir 50 mg tablet taken q.d. by mouth.

DRUG

Ruzasvir

Part A: six ruzasvir 10 mg (60 mg total daily dose) capsules taken q.d. by mouth.

DRUG

MK-3682B

Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.

DRUG

Ribavirin (RBV)

Part B and Part C: RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02332720 - Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) | Biotech Hunter | Biotech Hunter